Press Releases

Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec

First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline

- Late-breaking oral abstract presented at the World Congress of Gastroenterology -

- Understand AD: A Day in the Life, Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy and Understanding of this Unrelenting, Chronic Disease -

- Praluent continues to be available to patients in the U.S. -

- First targeted biologic in the European Union to receive marketing authorization for use in atopic dermatitis -

- In preclinical studies, trispecific antibodies show exceptional potency against diverse HIV viruses -

- Investigational RNAi Therapeutic Patisiran Meets Primary and All Secondary Endpoints, with Highly Significant Reduction In Neuropathy Progression and Improvement in Quality of Life at 18 Months Relative to Placebo -

- Late-breaking oral abstract of Phase 3 CAFÉ study presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress -

-- More adults reached HbA(1c) target at 8 and 12 weeks versus those receiving insulin glargine 100 Units/mL --

- Investigational dupilumab reduced severe asthma attacks and improved lung function -

- An innovative quadrivalent influenza vaccine will complement Sanofi Pasteur vaccine portfolio -

- Health care providers anticipating initial shipments by early August to kick off influenza immunization season -

- Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio -

- Data presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) -

- New DELIVER 3 Real-World Toujeo® Observational Study Confirms Reduction of Hypoglycemia in Real-Life Setting -

- All subgroups treated with Soliqua 100/33 achieved a mean HbA1c of below 7 percent after 30 weeks -

- Oral presentation provides first REGN2810 data in patients with advanced cutaneous squamous cell carcinoma (CSCC) -

- Kevzara is now available to U.S. patients -

-- New Initiative Encourages Americans to Help Reduce Air Pollution & Enjoy the Outdoors this Spring Allergy Season --

Op-Ed by Olivier Brandicourt

- New U.S. survey reveals significant unmet needs when it comes to treatments and support for those living with RA -

- New action date for Kevzara U.S. BLA is May 22, 2017 -

- Monthly dosing schedule now approved in both United States and European Union -

- New U.S. indication approved for Thymoglobulin [anti-thymocyte globulin (rabbit)]; first since 1998 -

- New toothpaste introduced by the trusted leader in mouthwashes for more than 30 years helps motivate kids to brush their teeth -

- DELIVER 2 Data Showed Reduction in Hypoglycemic Events Related to Inpatient or Emergency Department Visits -

- Dupixent will be available later this week to U.S. patients suffering from this chronic and debilitating form of eczema -

- During Multiple Myeloma Month Sanofi Genzyme is Reinforcing its Commitment to Help Patients Live with the Second Most Common Blood Cancer in the World -

The makers of Xyzal® Allergy 24HR, now available over-the-counter (OTC) at full prescription strength, are teaming up with Dr. Neeta Ogden to Encourage Allergy Sufferers to 'Wise Up, Rise Up'

Respiratory Syncytial Virus is the most common cause of lung inflammation and pneumonia in infants

- Late-breaking oral abstract to be presented today at the Annual Meeting of the American Academy of Dermatology -

- Praluent continues to be available to patients in the U.S. -